Klarsen specializes in data marketing for customer winning and engagement. Thanks to its qualified data and proprietary technologies, it allows its customers to increase their marketing performance and net sales. Klarsen disposes of proprietary assets and qualified and reactive databases, in its network of partners and on its own.

Employees

Sector

IT Services & Consulting

More about the company

Quotes

Date	Price	Change	Volume
24/26/24	€0.5600	+47.37%	8,278
23/26/23	€0.3800	0.00%	0
22/26/22	€0.3800	0.00%	0
21/26/21	€0.3800	0.00%	0
20/26/20	€0.3800	0.00%	0

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Market Closed - Euronext Paris Other stock markets 09:25:00 24/07/2026 pm IST			5-day change	1st Jan Change
0.5600 ^EUR	+47.37%		+47.37%	-35.48%

03/11	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/25/30	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Market Cap	28.76L 32.75L 26.75L 24.54L 46.12L 32Cr 46.83L 3.18Cr 1.24Cr 16Cr 1.23Cr 1.2Cr 54Cr	P/E 2023	3.28x	P/E 2024	-86x
Enterprise Value	39.57L 45.05L 36.8L 33.77L 63.45L 43Cr 64.42L 4.37Cr 1.71Cr 21Cr 1.69Cr 1.65Cr 74Cr	EV / Sales 2023	1.67x	EV / Sales 2024	0.82x
Free-Float	89.06%	Yield 2023 *	-	Yield 2024	-

03/11	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/25/30	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2024	CI
16/24/16	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2024	CI
30/24/30	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2023	CI
15/24/15	Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development	MT
07/23/07	Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results	MT
27/23/27	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2023	CI
28/23/28	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2022	CI
09/23/09	Acticor Biotech Secures Funding Until November After EUR12 Million Equity Raise; Stock Sinks 17%	MT
23/22/23	Acticor Biotech Seeks To Meet With US FDA Over Phase 2/3 Study Of Stroke Drug	MT
14/22/14	Twitter to shut down newsletter product Revue next year	RE
06/22/06	Acticor Biotech Wins EU Health Agency Nod For Phase 2/3 Stroke Study Design	MT
06/22/06	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2022	CI

03/03	Klarsen : ALKLA information relative au nombre total de droits de vote et d'actions composant le capital	PU
25/02	Klarsen : ALKLA-Information relative au nombre de droits de vote et actions composant le capital	PU
10/12	Klarsen : ALKLA-Attribution gratuite de BSA	PU
09/12	Klarsen : ALKLA-ACTIVITE 3T2025	PU
27/11	Klarsen : ALKLA-Résultat augmentation de capital	PU

Klarsen Share Price

Stocks

ALKLA

FR0011038348

IT Services & Consulting

Valuation: Klarsen

Chart: Klarsen

Latest news : Klarsen

Press Releases: Klarsen

News in other languages: Klarsen

Quotes and Performance

Course Extremes

Managers and Directors: Klarsen

Latest insider transactions

Other IT Services & Consulting

Financials

Company Profile

Quotes

Income Statement and Estimates

24/07	Klarsen : ALKLA – Klarsen annonce la résolution amiable de son litige avec la société PADAM – 24 Juillet 2026
24/07	Klarsen : ALKLA-Résolution litige PADAM à l'amiable
22/07	KLARSEN : Rapport Financier Annuel 2025
22/07	Klarsen : Information réglementée – 2025
22/07	Klarsen : ALKLA-Annexe résultat 2025

1 day	+47.37%
1 week	+47.37%
Current month	+47.37%
1 month	+47.37%
3 months	+106.64%
6 months	-47.17%
Current year	-35.48%

1 week	0.38	0.56
1 month	0.38	0.56
Current year	0.22	1.18
1 year	0.22	1.18
3 years	0.22	4.03
5 years	0.22	4.03
10 years	0.11	5.4

Manager	Title	Age	Since
Brice Gazeau CEO	Chief Executive Officer	-	-
Patrice Coffe DFI	Director of Finance/CFO	57	01/07/2008
Jean-Pierre Domingo CTO	Chief Tech/Sci/R&D Officer	-	01/01/2013

Director	Title	Age	Since
Patrice Coffe BRD	Director/Board Member	57	14/06/2010
Gérard Parrou BRD	Director/Board Member	74	27/06/2014
Frédéric Bartoli BRD	Director/Board Member	-	23/03/2011

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/03/22	Parrou Julien	Buy		2,617	0.0790%
28/02/22	Julien Parrou-Duboscq	Buy	Chief Executive Officer	3,011	0.0909%
28/02/22	Julien Parrou-Duboscq	Buy	Chief Executive Officer	11,500	0.3471%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KLARSEN	+47.37%	+47.37%	-32.37%	-82.98%	21.13L
IBM	+3.65%	+0.71%	-17.78%	+53.50%	20TCr
SNOWFLAKE INC.	+1.11%	-0.31%	+24.67%	+53.35%	9.29TCr
ACCENTURE PLC	+5.95%	+2.38%	-47.82%	-53.08%	8.99TCr
TATA CONSULTANCY SERVICES LTD.	+0.51%	-0.65%	-28.39%	-33.59%	8.47TCr
RELX PLC	+4.77%	+2.88%	-35.35%	-0.54%	5.98TCr
INFOSYS LIMITED	-0.62%	-5.07%	-32.95%	-22.12%	4.38TCr
HCL TECHNOLOGIES LIMITED	+2.11%	+5.57%	-15.67%	+14.21%	3.57TCr
FUJITSU LIMITED	+1.08%	-0.58%	+0.89%	+78.45%	3.47TCr
NEC CORPORATION	+0.21%	-2.41%	+2.83%	+208.57%	3.44TCr
Average	+6.02%	+4.99%	-18.19%	+21.58%	6.78TCr
Weighted average by Cap.	+0.87%	+0.47%	-17.69%	+25.88%

	2023	2024
Net sales	50.26L 57.22L 46.74L 42.89L 80.59L 55Cr 81.83L 5.55Cr 2.17Cr 27Cr 2.15Cr 2.1Cr 94Cr	63.11L 71.85L 58.69L 53.86L 1.01Cr 69Cr 1.03Cr 6.97Cr 2.72Cr 34Cr 2.7Cr 2.64Cr 117.62Cr
Net income	27.51L 31.32L 25.58L 23.47L 44.11L 30Cr 44.79L 3.04Cr 1.19Cr 15Cr 1.18Cr 1.15Cr 51Cr	-47.76T -54.38T -44.42T -40.76T -76.59T -52.37L -77.77T -5L -2L -25.75L -2L -2L -89.02L
Net Debt	-6L -7L -6L -5L -10.17L -6.96Cr -10.33L -70.06L -27.37L -3.42Cr -27.12L -26.53L -12Cr	10.81L 12.31L 10.05L 9L 17.33L 12Cr 17.6L 1.19Cr 46.63L 5.83Cr 46.19L 45.2L 20Cr